Our law firm is filing potential claims on behalf of shareholders of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC), over possible violations of US securities laws.
In December 2019, Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) agreed to pay over $1.2 billion to settle a shareholder lawsuit over allegations of US securities law violations.
This settlement is one of the larger shareholder lawsuit settlements in recent history.
The shareholder lawsuit was filed against VRX due to allegations of fraudulent practices by management that may have caused VRX investors to face significant losses. The lawsuit stemmed from reports that claimed that Valeant Pharmaceuticals International Inc. refilled patients’ prescriptions without their permission and steered them to more expensive drugs in order to boost sales and profits, leading to investors to potentially overvalue the company.
The settlement covers investors that purchased VRX between January 4, 2013 and March 15, 2016. If you purchased VRX shares between those dates, contact our law firm immediately to protect your rights. This is a time sensitive matter, and failure to act before certain established dates may cause you to forfeit your rights.
Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) investors may be able to collect significant financial compensation for their losses. The recent settlement with the company has set aside potentially hundreds of millions of dollars for compensating shareholders.
Did you purchase Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) stock between January 4, 2013 to March 15, 2016?, complete the form on this page or call 1-800-934-2921 right now to protect your rights.